Observational studyAnnals of African medicine2026
Programmed Death Ligand-1 Expression and Its Determinants in Patients with Lung Cancer: A Tertiary Care Center Experience in India.
Observational study in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTargeted therapy and immunotherapy have improved survival and quality of life in advanced lung cancer. In this study, we evaluated the frequency of programmed death ligand-1 (PDL-1) expression in lung cancer and its association with different clinical and histological subtypes. MATERIALS AND
methodsIt is a descriptive observational study, in which patients diagnosed with lung cancer were included. PDL-1 testing was done using the monoclonal antibody PDL-1 SP263 primary antibody. The association between the PLD-1 expression with the clinical parameters and histological grading of the disease was analyzed using the Chi-square test.
resultsOne hundred and fifty patients were included in our study. The majority of the patients had nonsmall cell lung cancer (90.7%). Among these, 78.7% had adenocarcinoma, 19.1% had squamous cell cancer, and only 2.2% had adeno-squamous cancer. Thirty percent were PDL-1 positive. In patients who were PDL-1 positive, high PDL-1 expression (tumor proportion score ≥50%) was seen in 40%. There was no significant difference seen in PDL-1 expression among different histological subtypes. A significant association of PDL-1 expression was seen with the young age group (34.8% below 60 years vs. 22% above 60 years), and history of tobacco chewing (42% vs. 27%). It was also seen more in men, nonsmokers, in those without history of biomass fuel exposure, less advanced stage, and with no history of pleural invasion. In patients with adenocarcinoma, significantly high PDL-1 expression was seen in those who were negative for EGFR mutation.
conclusionOur study has found new and different associations between PDL-1 expression and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.